Literature DB >> 20642441

Understanding the role of aldose reductase in ocular inflammation.

U C S Yadav1, S K Srivastava, K V Ramana.   

Abstract

Aldose reductase, although identified initially as a glucose-reducing enzyme via polyol pathway, is believed to be an important component of antioxidant defense system as well as a key mediator of oxidative stress-induced molecular signaling. The dual role played by AR has made it a very important enzyme for the regulation of not only the cellular redox state by detoxifying the reactive lipid-aldehydes generated by lipid peroxidation which is crucial in the cellular homeostasis, but also in the regulation of molecular signaling cascade that may regulate oxidative stress-induced cytotoxic events. Search for the new molecular targets to restrain the oxidative stress-induced inflammation has resulted in the identification of AR as an unanticipated mediator of oxidative stress-induced signaling. Although, in last one decade or so AR has been implicated in various inflammation-related diseases conditions ranging from diabetes, sepsis, cancer, cardiovascular and ocular inflammation, however, a critical evaluation of the clinical efficacy of AR inhibitors awaits a better understanding of the role of AR in regulating inflammation, especially in ocular inflammation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20642441      PMCID: PMC2912437          DOI: 10.2174/1566524011009060540

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  148 in total

Review 1.  Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.

Authors:  P F Kador; J H Kinoshita; N E Sharpless
Journal:  J Med Chem       Date:  1985-07       Impact factor: 7.446

2.  Distribution of aldose reductase in ocular tissues.

Authors:  T S Kern; R L Engerman
Journal:  Exp Eye Res       Date:  1981-08       Impact factor: 3.467

3.  Inhibitory effects of pyrrolidine dithiocarbamate on endotoxin-induced uveitis in Lewis rats.

Authors:  Kouichi Ohta; Kohzo Nakayama; Toru Kurokawa; Takanobu Kikuchi; Nagahisa Yoshimura
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-03       Impact factor: 4.799

Review 4.  Herpes simplex uveitis.

Authors:  Carmen Santos
Journal:  Bol Asoc Med P R       Date:  2004 Mar-Apr

Review 5.  Current perspectives on ophthalmic mycoses.

Authors:  Philip A Thomas
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

Review 6.  Intraocular lymphoma: update on diagnosis and management.

Authors:  Chi-Chao Chan; Dana J Wallace
Journal:  Cancer Control       Date:  2004 Sep-Oct       Impact factor: 3.302

7.  Prevention of endotoxin-induced uveitis in rats by benfotiamine, a lipophilic analogue of vitamin B1.

Authors:  Umesh C S Yadav; Sumitra Subramanyam; Kota V Ramana
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-01-10       Impact factor: 4.799

8.  Isolated unilateral acute retinal necrosis syndrome as the initial manifestation of HIV infection.

Authors:  Sujit Gharai; Pradeep Venkatesh; Satpal Garg; Surendra K Sharma; Prapti Ghosh Gharai; Rajpal Vohra
Journal:  AIDS Read       Date:  2009 Jun-Jul

9.  Rubella virus-associated uveitis: clinical manifestations and visual prognosis.

Authors:  Lenneke de Visser; Arthur Braakenburg; Aniki Rothova; Joke H de Boer
Journal:  Am J Ophthalmol       Date:  2008-06-10       Impact factor: 5.258

Review 10.  The dynamics of leukocyte infiltration in experimental autoimmune uveoretinitis.

Authors:  Emma C Kerr; David A Copland; Andrew D Dick; Lindsay B Nicholson
Journal:  Prog Retin Eye Res       Date:  2008-08-03       Impact factor: 21.198

View more
  15 in total

Review 1.  A potential therapeutic role for aldose reductase inhibitors in the treatment of endotoxin-related inflammatory diseases.

Authors:  Saumya Pandey; Satish K Srivastava; Kota V Ramana
Journal:  Expert Opin Investig Drugs       Date:  2012-01-28       Impact factor: 6.206

Review 2.  Emerging role of antioxidants in the protection of uveitis complications.

Authors:  U C S Yadav; N M Kalariya; K V Ramana
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

3.  Molecular cloning and characterization of Schistosoma japonicum aldose reductase.

Authors:  Jian Liu; Jipeng Wang; Shuqi Wang; Bin Xu; Xiufeng Liu; Xiaoning Wang; Wei Hu
Journal:  Parasitol Res       Date:  2012-11-17       Impact factor: 2.289

4.  Aldose reductase deficiency protects from autoimmune- and endotoxin-induced uveitis in mice.

Authors:  Umesh C S Yadav; Mohammed Shoeb; Satish K Srivastava; Kota V Ramana
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-17       Impact factor: 4.799

5.  ALDOSE REDUCTASE: New Insights for an Old Enzyme.

Authors:  Kota V Ramana
Journal:  Biomol Concepts       Date:  2011-04-01

6.  Antidiabetic drug metformin suppresses endotoxin-induced uveitis in rats.

Authors:  Nilesh M Kalariya; Mohammad Shoeb; Naseem H Ansari; Satish K Srivastava; Kota V Ramana
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-08       Impact factor: 4.799

Review 7.  4-Hydroxynonenal in the pathogenesis and progression of human diseases.

Authors:  Mohammad Shoeb; Naseem H Ansari; Satish K Srivastava; Kota V Ramana
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

8.  Neuroprotective effect of aldose reductase knockout in a mouse model of spinal cord injury involves NF-κB pathway.

Authors:  Fu-Xin Han; Rui Zhang; Xin-Xing Yang; Shan-Bo Ma; Shi-Jie Hu; Bing Li
Journal:  Exp Brain Res       Date:  2022-01-23       Impact factor: 1.972

9.  Deletion of aldose reductase from mice inhibits diabetes-induced retinal capillary degeneration and superoxide generation.

Authors:  Jie Tang; Yunpeng Du; J Mark Petrash; Nader Sheibani; Timothy S Kern
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

Review 10.  Aldose Reductase: a cause and a potential target for the treatment of diabetic complications.

Authors:  Sapna Thakur; Sonu Kumar Gupta; Villayat Ali; Priyanka Singh; Malkhey Verma
Journal:  Arch Pharm Res       Date:  2021-07-19       Impact factor: 4.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.